This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Preliminary Results Of Prospective Trial Suggest Warfarin May Be A Safer Option For Patients Than Alternative Therapies

Today, at the 2012 Thrombosis and Hemostasis Summit of North America, Alere Inc. (NYSE: ALR) announced preliminary results from the largest study to date comparing warfarin (Coumadin®) and dabigatran (Pradaxa®) therapies administered in a real-world setting. The study was performed by Mark Wurster, MD, anticoagulation expert and Chief Medical Officer of Standing Stone, Inc., an Alere subsidiary. Findings reveal that complications necessitating therapy discontinuation occurred more frequently with dabigatran than with warfarin. Additionally, complications related to dabigatran appeared very early in treatment, with patients reporting issues, on average, after just less than four months of therapy.

Dabigatran (Pradaxa®) is the first oral thrombin/Xa inhibitor cleared for use by the FDA in the United States. Commercially available since November 2010, the medication is intended for the prevention of thromboembolic complications related to atrial fibrillation. While pre-approval studies are numerous, reporting on the use of dabigatran after commercial release in real-world settings has generally been limited to individual cases. Moreover, little information is available about the frequency of side effects or complications for patients on dabigatran, especially in comparison to patients receiving warfarin therapy administered by organized anticoagulation clinics.

The “Dabigatran in the Real World” study was conducted at a large anticoagulation clinic managing 2,200 patients on oral therapy. Beginning in November 2010, all clinic patients whose prescribing physicians requested a switch from warfarin to dabigatran were tracked prospectively for a one-year period. Each patient served as his or her own control, and primary outcome measures focused on clinical events that led to the discontinuation of dabigatran or warfarin. These include episodes of thrombosis, bleeding, treatment-related death and any other events that required therapy with either agent to be discontinued.

Results for each patient were obtained from the first six months of dabigatran use and compared to the prior six months of treatment on warfarin. A total of 113 patients had evaluable data; the mean exposure times to dabigatran and warfarin were 3.9 and 6 months, respectively. During the warfarin treatment period, primary outcomes included one hospitalization with the diagnosis of warfarin toxicity. During the dabigatran treatment period, primary outcomes included: one treatment-related death (GI bleed); four other bleeding episodes (two GI bleeds, one rectus sheath hemorrhage, one intracranial hemorrhage associated with trauma); one episode of deep venous thrombosis; one atrial thrombus; one transient ischemic attack; one skin rash; and four incidents of gastrointestinal symptoms requiring cessation of dabigatran. The frequency of primary outcomes during the warfarin treatment phase was 0.88%, compared to 11.5% during the dabigatran treatment phase (p < 0.0014).

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,105.22 +18.59 0.11%
S&P 500 1,990.70 +3.69 0.19%
NASDAQ 4,481.3540 +7.6570 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs